Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance

　　1.Mechanism and the"Resistance"Misconception

　　Acoramidis is an oral medication for transthyretin amyloid cardiomyopathy(ATTR-CM).Its primary action is to stabilize TTR tetramers and reduce TTR dissociation,thereby slowing disease progression and lowering the risk of cardiovascular death and related hospitalizations.It is important to note that the drug does not cause existing myocardial amyloid deposits to disappear immediately.

　　Unlike some oncology targeted therapies,acoramidis currently has no clinically established,test-based criteria for acquired resistance.Therefore,if a patient experiences no further symptom improvement or a decline in cardiac function during treatment,this cannot be directly attributed to"drug resistance."Disease progression itself does not equate to treatment failure.

　　2.Proper Assessment of Clinical Changes

　　When exercise tolerance decreases,dyspnea worsens,edema develops,or heart failure hospitalizations recur,clinicians should differentiate among several possibilities:

　　Natural disease progression:ATTR-CM is a chronic progressive condition;wild-type and hereditary variants follow different trajectories.

　　Heart failure management changes:Alterations in concomitant medications,dietary sodium/fluid restrictions,etc.

　　Medication non-adherence:Missed doses or irregular intake can lead to inadequate drug exposure.This should be ruled out before concluding resistance.

　　3.Dosing and Administration

　　The recommended dose is 712 mg daily(two 356 mg tablets twice daily),taken with or without food.Tablets must be swallowed whole—do not split,crush,or chew.Patients must adhere to the FDA-approved dose and should never self-increase the dose in response to worsening symptoms.

　　4.Comprehensive Evaluation and Treatment Adjustment

　　For patients with confirmed progressive disease,evaluation should integrate echocardiography,electrocardiography,cardiac biomarkers(e.g.,NT-proBNP),and clinical symptoms.Treatment decisions should not rely on a single test result.Any adjustment to the overall ATTR-CM management strategy requires confirmation of diagnosis type,adherence status,actual dose,and cardiac function trends,followed by a thorough physician assessment.

　　5.Conclusion

　　Clinical worsening during acoramidis therapy is not synonymous with resistance.The rational approach is to verify adherence and drug exposure first,then assess disease status through multidimensional testing,and finally determine whether the overall treatment plan needs modification.